Abstract
The amyloid β-peptide (Aβ) plays an early and critical role in the pathogenic cascade leading to Alzheimers disease (AD). Aβ is typically found in extracellular amyloid plaques that occur in specific brain regions in the AD and Down syndrome brain. Mounting evidence, however, indicates that intraneuronal accumulation of this peptide may also contribute to the cascade of neurodegenerative events that occur in AD and Down syndrome. A pathogenic role for intracellular Aβ is not without precedent, as it is known to be an early and integral component of the human muscle disorder inclusion body myositis (IBM). Therefore, it is plausible that intracellular Aβ may likewise induce cytopathic effects in the CNS, causing neuronal and synaptic dysfunction and perhaps even neuronal loss. Here we review recent evidence supporting a pathogenic role for intracellular Aβ in AD, Down syndrome, and IBM.
Keywords: parkinsons disease, amyotrophic lateral sclerosis, amyloid plaques, inclusion body myositis, alzheimers disease, paired helical filaments, brain
Current Alzheimer Research
Title: Amyloid β-Peptide: The Inside Story
Volume: 1 Issue: 4
Author(s): Bertrand P. Tseng, Masashi Kitazawa and Frank M. LaFerla
Affiliation:
Keywords: parkinsons disease, amyotrophic lateral sclerosis, amyloid plaques, inclusion body myositis, alzheimers disease, paired helical filaments, brain
Abstract: The amyloid β-peptide (Aβ) plays an early and critical role in the pathogenic cascade leading to Alzheimers disease (AD). Aβ is typically found in extracellular amyloid plaques that occur in specific brain regions in the AD and Down syndrome brain. Mounting evidence, however, indicates that intraneuronal accumulation of this peptide may also contribute to the cascade of neurodegenerative events that occur in AD and Down syndrome. A pathogenic role for intracellular Aβ is not without precedent, as it is known to be an early and integral component of the human muscle disorder inclusion body myositis (IBM). Therefore, it is plausible that intracellular Aβ may likewise induce cytopathic effects in the CNS, causing neuronal and synaptic dysfunction and perhaps even neuronal loss. Here we review recent evidence supporting a pathogenic role for intracellular Aβ in AD, Down syndrome, and IBM.
Export Options
About this article
Cite this article as:
Tseng P. Bertrand, Kitazawa Masashi and LaFerla M. Frank, Amyloid β-Peptide: The Inside Story, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043332045
DOI https://dx.doi.org/10.2174/1567205043332045 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of a Series of Acidic Drugs on L-Lactic Acid Transport by the Monocarboxylate Transporters MCT1 and MCT4
Current Pharmaceutical Biotechnology Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Macrolides Allergy
Current Pharmaceutical Design A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin
Current Diabetes Reviews Hypocholesterolemia
Current Vascular Pharmacology Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Prevalence of <i>Toxoplasma gondii</i> and <i>Toxocara canis</i> Among Myositis Patients in the Southwest of Iran
Infectious Disorders - Drug Targets Concurrent Methicillin-Resistant <i>Staphylococcus aureus Septicemia</i> and Thyroid Abscess in a Young Male with Dengue
Infectious Disorders - Drug Targets Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Relationship Between Polymorphisms of Interleukin-1 Receptor Antagonist (IL-1Ra) Genes and Susceptibility to Systemic Lupus Erythematosus in Iranian Population
Current Rheumatology Reviews Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Advances in Drug Therapy for Systemic Lupus Erythematosus
Current Medicinal Chemistry Preparation and Characterisation of Alendronate-Loaded Chitosan Microparticles Obtained Through the Spray Drying Technique
Medicinal Chemistry Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews